Please assess the completion status of the following clinical trial:

Trial Title: Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Kidney transplant recipients with confirmed transplant glomerulopathy on kidney biopsy.~* Failed standard therapy (\>25% reduction in proteinuria) including maximum use of an ACE inhibitor, ARB, or aldosterone blocker with a goal blood pressure less than 130/80 and optimization of their immunosuppression~Exclusion Criteria:~* Diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Acthar (Type: EXPERIMENTAL): Acthar 80 units twice weekly for 6 months. If endpoint is not reached, duration may be increased to 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).